J&J: RYBREVANT Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial

(RTTNews) - Johnson & Johnson (JNJ) announced that updated results from the Phase 3 MARIPOSA-2 study showed that combining RYBREVANT (amivantamab-vmjw) with chemotherapy provided consistent benefits across post-progression outcomes for adult patients with previously treated non-s https://www.nasdaq.com/articles/jj-rybrevant-chemotherapy-shows-strong-benefits-and-improved-survival-phase-3-nsclc-trial